Market Overview
The European cancer vaccines market forms part of the broader European vaccines market, which reached $10.53 billion in 2024 and is projected to grow to $13.74 billion by 2030. Within this landscape, the global cancer vaccines market was valued at approximately $11.62 billion in 2025, with Europe representing a significant regional share. European healthcare systems invested approximately €146 billion in cancer care in 2023, creating a substantial foundation for the adoption of innovative vaccine therapies.
- •European vaccines market valued at $10.53 billion in 2024, projected to reach $13.74 billion by 2030
- •Global cancer vaccines market stood at $11.62 billion in 2025 with Europe as a key regional contributor
- •Europe's healthcare systems spent €146 billion on cancer care in 2023
Growth Drivers
Rising cancer prevalence across Europe, combined with aging populations and increased screening programs, creates growing demand for both preventive and therapeutic cancer vaccines. Breakthroughs in mRNA and personalized vaccine technologies have accelerated clinical development, while favorable regulatory pathways and healthcare reimbursement policies in major European markets support market expansion. The personalized cancer vaccine segment is experiencing particularly explosive growth, with the European market expanding from $84 million in 2025 toward billions by the mid-2030s.
- •Personalized cancer vaccine market in Europe projected at 43.77% CAGR from 2026 to 2035
- •Therapeutic cancer vaccines gaining traction alongside preventive HPV vaccines
- •mRNA platform advancements reducing development timelines and improving efficacy
Segmentation and Regional Analysis
The European market is characterized by strong concentration in Western Europe, particularly Germany, the United Kingdom, France, and the Nordic countries, which host major pharmaceutical R&D centers and advanced healthcare infrastructure. The market spans preventive vaccines targeting virus-associated cancers such as cervical cancer through HPV immunization programs, alongside a rapidly growing segment of therapeutic vaccines for melanoma, lung cancer, and other malignancies. The personalized cancer vaccine sub-market is emerging as the fastest-growing category, with Europe positioned as the second-largest regional market globally.
- •Germany, UK, France, and Scandinavia lead in R&D infrastructure and early adoption
- •HPV vaccination programs represent established preventive segment across EU nations
- •Personalized cancer vaccines projected to reach $3.18 billion in Europe by 2035
Trends and Outlook
What are the recent trends and outlook?
Integration of artificial intelligence and neoantigen prediction technologies is accelerating the development of personalized cancer vaccines, with several candidates advancing through late-stage clinical trials in Europe. Combination therapies pairing cancer vaccines with checkpoint inhibitors and other immunotherapies are showing enhanced efficacy, suggesting future treatment paradigms will involve multi-modal approaches. The market is expected to maintain robust growth through 2030, with the segment's trajectory positioned to accelerate further as personalized medicine becomes standard practice in European oncology care.
- •AI-driven neoantigen identification streamlining personalized vaccine development
- •Combination immunotherapy regimens showing superior response rates in clinical studies
- •Market expansion supported by EMA accelerated approval pathways for innovative therapies
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.